
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
Catalyzing Cardiovascular Health Innovation through Urban Interventions and Collaborative Research
Cardiovascular health innovation is at the forefront of the Innovative Health Initiative (IHI), the world's largest public-private partnership in life sciences, which succeeds the Innovative Medicines Initiative (IMI). Key projects from IHI Call 8, such as Cities@Heart, target cardiovascular dise...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
Johnson & Johnson has submitted a Type II variation application to the European Medicines Agenc...
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
European Cancer Care has achieved substantial improvements in survival rates without a disproportionate escalation in health budgets, as evidenced by the